# **Accepted Manuscript**

The Safety and Efficacy of an Alcohol-free Pancreatic Cyst Ablation Protocol

Matthew T. Moyer, Setareh Sharzehi, Abraham Mathew, John M. Levenick, Brandy D. Headlee, Jonathan T. Blandford, Heather D. Heisey, James H. Birkholz, Brooke B. Ancrile, Jennifer L. Maranki, Niraj J. Gusani, Thomas J. McGarrity, Charles E. Dye



PII: S0016-5085(17)36020-1 DOI: 10.1053/j.gastro.2017.08.009

Reference: YGAST 61350

To appear in: Gastroenterology Accepted Date: 1 August 2017

Please cite this article as: Moyer MT, Sharzehi S, Mathew A, Levenick JM, Headlee BD, Blandford JT, Heisey HD, Birkholz JH, Ancrile BB, Maranki JL, Gusani NJ, McGarrity TJ, Dye CE, The Safety and Efficacy of an Alcohol-free Pancreatic Cyst Ablation Protocol, *Gastroenterology* (2017), doi: 10.1053/j.gastro.2017.08.009.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

### ACCEPTED MANUSCRIPT

## The Safety and Efficacy of an Alcohol-free Pancreatic Cyst Ablation Protocol

Matthew T. Moyer, <sup>1</sup> Setareh Sharzehi, <sup>1</sup> Abraham Mathew, <sup>1</sup> John M. Levenick, <sup>1</sup> Brandy D. Headlee, <sup>1</sup> Jonathan T. Blandford, <sup>3</sup> Heather D. Heisey, <sup>4</sup> James H. Birkholz, <sup>5</sup> Brooke B. Ancrile, <sup>1</sup> Jennifer L. Maranki, <sup>1</sup> Niraj J. Gusani, <sup>2</sup> Thomas J. McGarrity, <sup>1</sup> Charles E. Dye<sup>1</sup>

<sup>1</sup>Division of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, Pennsylvania; <sup>2</sup>Division of Surgical Oncology, Penn State Hershey Medical Center, Hershey, Pennsylvania; <sup>3</sup>University Endoscopy Center, Penn State Hershey Medical Center, Hershey Pennsylvania; <sup>4</sup>Penn State Hershey Investigational Pharmacy, Penn State Hershey Medical Center, Hershey, Pennsylvania; <sup>5</sup>Department of Radiology, Penn State Hershey Medical Center, Hershey, Pennsylvania.

Corresponding Author: Matthew T. Moyer, MD, MS

Associate Professor of Medicine, Division of Gastroenterology & Hepatology

Penn State Hershey Medical Center and Penn State Cancer Institute

500 University Drive, PO Box 850, Mail Code HU33

Hershey PA, USA 17033-0850

Tel.1-717-531-3694, Fax.1-717-531-6770, Email: <a href="mmoyer@pennstatehealth@psu.edu">mmoyer@pennstatehealth@psu.edu</a>

#### **Author Contributions:**

Study concept and design: Matthew T. Moyer, MD, MS.

Acquisition of data: Matthew T. Moyer, MD, MS, Charles E. Dye, MD, Abraham Mathew, MD, MSc,

Brandy D. Headlee, PA-C, James H. Birkholz, M.D.

Drafting of the manuscript: Matthew T. Moyer, MD, MS.

Critical revision of the manuscript for important intellectual content: all authors.

Administrative, technical or material support: Setareh Sharzehi, MD, Jonathan T. Blandford, Heather D. Heisey, R.Ph.

Statistical analysis: Setareh Sharzehi, MD, Matthew T. Moyer, MD, MS, Brooke Ancrile, PhD. Study Supervision: Matthew T. Moyer, MD, MS, Setareh Sharzehi, MD, Brooke Ancrile, PhD.

**Potential conflicts of interest:** Matthew T. Moyer, MD, MS (Consultant, Boston Scientific Inc.) Abraham Mathew, MD, MSc (Consultant, Boston Scientific Inc.). All other authors have nothing to disclose.

**Financial Support:** Funding for the CHARM Trial provided by the Anne Brossman Sweigart Gift Fund (Budget fund #217-41 HY 44HP) Penn State Hershey Medical Center. Boston Scientific Inc. generously made an unrestricted donation of EUS-FNA needles for this project. Neither of these groups had any role in the design or conduct of the study, collection, analysis, interpretation of the data, nor the preparation, review or approval of the manuscript.

#### **Abbreviations:**

CA 19-9: carbohydrate antigen (cancer antigen) 19-9

CEA: Carcinoembryonic antigen

CHARM:  $\underline{Ch}$ emotherapy for  $\underline{A}$ blation and  $\underline{R}$ esolution of  $\underline{M}$ ucinous Pancreatic Cysts

CT: computed tomography

EUS-FNA: Endoscopic ultrasound- fine-needle aspiration EUS-FNI: Endoscopic ultrasound- fine-needle infusion

FOLFOX: Leucovorin, fluorouracil, oxaliplatin regimen

CHOP-R: Cyclophosphamide, doxorubicin, oncovin, prednisone, rituximab regimen

HPLC: High performance liquid chromatography IPMN: Intraductal papillary mucinous neoplasm

KRAS: V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

# Download English Version:

# https://daneshyari.com/en/article/8727496

Download Persian Version:

https://daneshyari.com/article/8727496

<u>Daneshyari.com</u>